Τίτλος:
Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naïve advanced or metastatic non-small cell lung cancer (NSCLC)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre-and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: p = 0.004), CEACAM5mRNA (p = 0.010), or by any assay (p = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: p = 0.000; overall survival; OS: p = 0.009), CEACAM5mRNA+ CTCs (PFS: p = 0.043; OS: p = 0.039), and CTCs by any assay (PFS: p = 0.005; OS: p = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; p = 0.001) and death (HR: 2.866; p = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (p = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre-and post-treatment was associated with reduced PFS (p = 0.036) and OS (p = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Papadaki, M.A.
Messaritakis, I.
Fiste, O.
Souglakos, J.
Politaki, E.
Kotsakis, A.
Georgoulias, V.
Mavroudis, D.
Agelaki, S.
Περιοδικό:
International Journal of Molecular Sciences
Λέξεις-κλειδιά:
anaplastic lymphoma kinase; docetaxel; epidermal growth factor receptor; gemcitabine; messenger RNA; pemetrexed; taxane derivative; vinorelbine tartrate; carcinoembryonic antigen; CEACAM5 protein, human; glycosylphosphatidylinositol anchored protein; tumor marker, adult; advanced cancer; aged; Article; bone metastasis; cancer chemotherapy; cancer combination chemotherapy; cancer patient; cancer risk; cancer staging; cancer survival; central nervous system metastasis; circulating tumor cell; clinical article; controlled study; disease exacerbation; drug efficacy; female; HCC827 cell line; human; human cell; human tissue; liquid biopsy; liver metastasis; lung metastasis; male; metastasis; monotherapy; non small cell lung cancer; overall survival; peripheral blood mononuclear cell; progression free survival; real time polymerase chain reaction; blood; disease free survival; metabolism; metastasis; middle aged; non small cell lung cancer; pathology; prognosis; tumor embolism; tumor recurrence, Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; GPI-Linked Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prognosis
DOI:
10.3390/ijms22020925
